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Abstract
Background: Despite the clear physical association between activated astrocytes and amyloid-β (Aβ) plaques,
the importance of astrocytes and their therapeutic potential in Alzheimer’s disease remain elusive. Soluble Aβ
aggregates, such as protofibrils, have been suggested to be responsible for the widespread neuronal cell death in
Alzheimer’s disease, but the mechanisms behind this remain unclear. Moreover, ineffective degradation is of great
interest when it comes to the development and progression of neurodegeneration. Based on our previous results
that astrocytes are extremely slow in degrading phagocytosed material, we hypothesized that astrocytes may be an
important player in these processes. Hence, the aim of this study was to clarify the role of astrocytes in clearance,
spreading and neuronal toxicity of Aβ.
Results: To examine the role of astrocytes in Aβ pathology, we added Aβ protofibrils to a co-culture system of
primary neurons and glia. Our data demonstrates that astrocytes rapidly engulf large amounts of Aβ protofibrils, but
then store, rather than degrade the ingested material. The incomplete digestion results in a high intracellular load
of toxic, partly N-terminally truncated Aβ and severe lysosomal dysfunction. Moreover, secretion of microvesicles
containing N-terminally truncated Aβ, induce apoptosis of cortical neurons.
Conclusions: Taken together, our results suggest that astrocytes play a central role in the progression of
Alzheimer’s disease, by accumulating and spreading toxic Aβ species.
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Background
Knowledge about the cellular mechanisms behind initi-
ation and spreading of Alzheimer’s disease (AD) is still
very limited. Decades of research have focused on neur-
onal abnormalities in AD pathology, but recently more
attention has been given to other cell types, including
astrocytes [1]. Being the most abundant glial cell type in
the nervous system, astrocytes are highly responsible for
maintaining brain homeostasis [2]. Their functions
include metabolic support of neurons, modification of
synapse signaling, recycling of neurotransmittors, regula-
tion of blood flow and contribution to the blood brain
barrier [2, 3]. In addition, astrocytes respond to all
pathological conditions through a process referred to as
reactive astrogliosis, in which the astrocytes convert to
an inflammatory state [4].
The amyloid cascade hypothesis suggests that amyloid-β
(Aβ) mis-metabolism is the main causative event in AD,
from which all other neuropathological features emanate
[5]. Due to its hydrophobic nature, Aβ monomers will ag-
gregate and form soluble aggregated species, which even-
tually deposit as senile plaques. A major concern with the
amyloid cascade hypothesis is that the number of plaques
does not correlate with the severity of dementia [6, 7].
However, results from different research groups indicate
that it is the presence of soluble Aβ aggregates, such as
oligomers and protofibrils, rather than the plaques that in-
duces the widespread neuronal death [8–12]. Protofibrils
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have been shown to be the predominant species of soluble
Aβ aggregates in both tg-ArcSwe mice and human AD
brains [13, 14]. Moreover, the levels of soluble Aβ aggre-
gates in cerebrospinal fluid (CSF) have been demonstrated
to be elevated in AD patients compared to controls and to
correlate with cognitive impairment [15–18].
There is compelling evidence that Aβ pathology is
closely associated with inflammation and reactive astro-
cytes and microglia are situated tightly around the pla-
ques [19]. The formation of a glial capsule around the
Aβ deposits may protect the surrounding brain tissue
from toxic Aβ species, but the astrocytes and microglia
have also been shown to secrete cytokines and neuro-
toxic products that could induce neuronal degeneration
[20]. Astrocytes effectively engulf dead cells, synapses
and protein aggregates of Aβ and α-synuclein [21–27].
Interestingly, astrocytes have been shown to be more ef-
ficient than microglia in taking up Aβ, particularly dur-
ing the early stages of AD [28]. The fact that reactive
astrocytes with high Aβ load are frequently found in the
AD brain further confirms the importance of astrocytes in
Aβ clearance [29]. Compared to macrophages, that start
to digest phagocytosed cell corpses directly, our group has
previously demonstrated that it takes almost two weeks
for astrocytes to degrade ingested, dead cells [26]. The in-
efficient degradation of dead cells by astrocytes is at least
partly due to long lasting actin-rings surrounding the pha-
gosomes, physically inhibiting the phagosome-lysosome
fusion [30]. It is known that a large phagocytic burden
could also inhibit degradation in professional phagocytes,
by prolonging the time actin surrounds the phagosome
[31]. Further, the astrocytes express high levels of Rab27a,
a protein that reduces the lysosome acidity [30].
Since the majority of the patients with sporadic AD do
not have an increased Aβ production, it has been
suggested that the main cause of this form of the disease
is instead insufficient lysosomal degradation [32, 33].
Moreover, it is known that patients with lysosomal stor-
age disorders often develop neurodegenerative diseases,
including AD and Parkinson’s disease [32, 34]. Ineffect-
ive degradation of Aβ may lead to spreading of AD path-
ology, due to secretion of Aβ-containing vesicles [35].
We hypothesized that astrocytes, due to their ineffective
digestion may be an important player in these processes
and the aim with the present investigation was to eluci-
date the role of astrocytes in Aβ42 protofibril clearance
and toxicity. Our data demonstrates that astrocytes en-
gulf large amounts of Aβ42 protofibrils that are stored in
the astrocytes for a long time, rather than being degraded.
This intracellular accumulation causes severe endosomal/
lysosomal defects that probably reduce the degradation
capacity of the astrocytes further. In addition, incomplete
degradation of Aβ42 protofibrils results in microvesicle-
induced neurotoxicity. Taken together, our results indicate
that slow degradation by astrocytes may be a key process
in Aβ pathology.
Results
Astrocytes engulf large amounts of Aβ42 protofibrils
In order to investigate the uptake of Aβ42 protofibrils by
the major cell types in the brain, we performed experiments
using co-cultures of cortical astrocytes, neurons and oligo-
dendrocytes. The cell cultures were exposed to fluorescent
HiLyte™ Fluor 555-labeled Aβ42 (Aβ42-555) protofibrils for
24 h, fixed and stained with specific antibodies to Glial Fi-
brillary Acidic Protein (GFAP), βIII tubulin and 2',3'-Cyclic-
nucleotide 3'-phosphodiesterase (CNPase), to label astro-
cytes, neurons and oligodendrocytes, respectively. We
found that astrocytes contained large amounts of Aβ42-
555 (Fig. 1a and Additional file 1), while almost no Aβ42-
555 could be detected in the neurons (Fig. 1b and Add-
itional file 1). Interestingly, the Aβ42-555 inclusions in the
astrocytes frequently co-localized with condensed, ter-
minal (TdT)-mediated dUTP-biotin (TUNEL) positive cell
nuclei of dead cells that had also been engulfed by the glial
cells (Fig. 1a and Additional file 2). Uptake of Aβ42-555
protofibrils was also noted in the oligodendrocytes
(Fig. 1c). However, the approximate percentage of oligo-
dendrocytes in the cultures is very low (6 % ± 3), com-
pared to the astrocytes (75 % ± 8) and neurons (25 % ± 8).
To confirm that the Aβ42-555 deposits were situated in-
side the astrocytes we used confocal microscopy. The 3D-
images clearly show that Aβ42-555 protofibrils were taken
up and predominantly localized around condensed nuclei
of dead cells inside the astrocytes (Fig. 1d and Additional
file 3). It is important to remember that GFAP stains the
cytoskeleton of the astrocyte, which only constitutes 15–
20 % of the cell [36]. Hence, the whole astrocyte is much
bigger than the GFAP staining and the Aβ42-555 found
close to the GFAP staining is most likely also situated in-
side the cell (Fig. 1d and Additional file 3).
To verify that the 555-label still bound to the Aβ after
the engulfment, parallel co-cultures were treated with
unlabeled Aβ42 protofibrils for 24 h, fixed and stained
with GFAP and four different Aβ antibodies; mAb1C3
and 6E10 (both binding to the N-terminus of Aβ),
mAb158 (selective for Aβ protofibrils) and a polyclonal
Aβ42 antibody. All antibodies displayed similar staining
pattern, as received with the Aβ42-555 protofibrils, dem-
onstrating that the 555-signal represents the presence of
Aβ (Additional file 4 A-D). To exclude that the degrad-
ation of Aβ42 protofibrils in astrocytes was influenced by
the neurons present in the co-culture, we performed
experiments with cell cultures differentiated in the
presence of cilliary neurotrophic factor (CNTF). CNTF
is known to drive E14 neural stem cells to generate
almost exclusively astrocytes [37, 38]. The astrocytes in
the CNTF-treated cultures were found to accumulate
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Aβ42 protofibrils in a similar way to those in the co-
cultures (Additional file 5). To follow the engulfment of
Aβ protofibrils over time we next performed time-lapse
experiments, in which we recorded the cell culture
during the 24 h Aβ42-555 protofibril exposure. Our time-
lapse movies demonstrate that already after 30 min, astro-
cytes (identified by their phenotype of an egg “sunny side
up”, large nuclei and multi-vesicular cytoplasm) had accu-
mulated Aβ42-555, and the intensity of the staining
constantly increased during the 24 h time period (Fig. 2a, b
and Additional file 6). In line with our results from the
immunostainings, very little of the Aβ42-555 protofibrils
co-localized with neurons (identified by their oval cell bod-
ies, distinct axons and active migration) (Fig. 2a, c and
Additional file 6).
The tg-ArcSwe mouse model is known to have ele-
vated levels of soluble Aβ aggregates including protofi-
brils, and AD-like Aβ plaque pathology with an onset
Fig. 1 Aβ42 protofibril deposits are found in glial cells, but not in neurons. Immunocytochemistry of co-cultures containing astrocytes, neurons
and oligodendrocytes demonstrates that astrocytes contain large deposits of Aβ42-555 (a). Neurons lack detectable Aβ42-555 levels (b), but the
few oligodendrocytes in the culture also contain Aβ42-555 (c). Confocal imaging confirms intracellular localization of large Aβ42-555 inclusions in
astrocytes (d). DAPI (blue), GFAP (green) and Aβ42-555 (red). Scale bars: a–c = 20 μm, d = 10 μm
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around six months of age [39–41]. Immunostainings of
brain sections from 12 to 14-month-old tg-ArcSwe mice,
using antibodies against GFAP and Aβ demonstrated
that astrocytes, as expected, were tightly localized
around Aβ plaques (Fig. 2d) and that Aβ co-localize with
astrocytes in vivo (Additional file 7). Interestingly, we
also found that some of the Aβ that had been ingested
by reactive astrocytes co-localized with condensed nuclei
of dead cells, confirming that our findings in the cell
cultures reflect cellular processes of Aβ pathology in
vivo (Fig. 2e).
Aβ protofibrils are accumulated in astrocytes for a very
long time
To follow the degradation of intracellular Aβ42 protofibrils
in astrocytes, neurons and oligodendrocytes, cell cultures
were thoroughly washed after the 24 h Aβ42-555 pro-
tofibril exposure and cultured for additional 6 or
12 days prior to fixation and staining. The cells were
divided into four categories; cells with no detectable
levels of Aβ42-555 (−), cells with only small amounts of
Aβ42-555 (+), cells containing medium sized Aβ42-555 in-
clusions or larger Aβ42-555 inclusions with low intensity
(++) and cells with one or more large Aβ42-555 inclusion
with high intensity (+++). The four categories in combin-
ation with GFAP staining are shown in Fig. 3a. Quantifica-
tion of the percentage of astrocytes in each category
demonstrates that most astrocytes contained large
inclusions of Aβ42-555 (+++) directly after the 24 h expos-
ure (63.5 ± 20.1 %). Although the percentage of (+++)
astrocytes had decreased significantly after 6 days
(30.7 ± 24.0 %, P < 0.001) and 12 days (33.8 ± 15.3 %
P < 0.001), the degradation was extremely slow. The per-
centage of astrocytes containing medium sized Aβ42-555
inclusions (++) was lower at 24 h (15.4 ± 11.0 %), but did
not decrease over time. Astrocytes containing small
amounts of Aβ42-555 (+) and astrocytes with no detect-
able levels of Aβ42-555 (−) increased significantly from
24 h (18.3 ± 16 % respective 2.6 ± 4.6 %) to 24 h +
6 days (30.0 ± 16.6 %, P = 0.0034 respective 22.6 ± 18.8 %,
P < 0.001). Taken together, these results demonstrate that
astrocytes effectively ingest Aβ42 protofibrils, but that the
Fig. 2 Aβ42 protofibrils accumulate intracellulary in astrocytes over time. Time-lapse images from 30 min to 24 h following Aβ42-555 protofibril
administration show that astrocytes (A), but not neurons (*), accumulate Aβ42-555 over time (a). Higher magnification of a highly vascularized astrocyte
with ingested Aβ42-555 (b) and a neuron with undetectable levels of intracellular Aβ42-555 (c). Immunohistochemistry of tg-ArcSwe mouse brain
sections confirm that Aβ plaques are surrounded by GFAP positive astrocytes, Aβ (red), GFAP (green) and DAPI (blue) (d) and that Aβ are engulfed by
astrocytes in vivo (e). Scale bars: a–d = 10 μm
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Fig. 3 Aβ42 are stored in astrocytes for a very long time. To follow degradation of intracellular Aβ42-555 in astrocytes following Aβ42-555
protofibril removal, cells were divided into four categories; cells with no detectable levels of Aβ42-555 (–), cells with only small amounts of Aβ42-555
(+), cells containing medium sized Aβ42-555 deposits (++) and cells with large Aβ42-555 inclusions (+++) (a). Astrocytes degrade Aβ42-555 protofibrils
very slowly and much Aβ42 remains in the cells 12 days after Aβ42-555 protofibril removal (b). Neurons contain almost no Aβ42 (c). The
few oligodendrocytes in the culture also degrade the Aβ42-555 protofibrils slowly (d). Although the glial cells degrade the Aβ42-555
protofibrils slowly, the total number of 555-stained inclusions (24 h: 10.4 ± 7.7; 24 h + 6 days: 7.9 ± 7.1; 24 h + 12 days: 6.2 ± 7.1) in the
culture decline significantly from 24 h to 24 h + 6 days (P = 0.013) and 24 h + 12 days (P < 0.001) (e). In line with these results, the total
555-intensity (24 h: 1.7 × 107 ± 8.5 × 106; 24 h + 6 days: 8.3 × 106 ± 5.1 × 106; 24 h + 12 days: 5.9 × 106 ± 4.3 × 106) (f) and total 555-positive
area (24 h: 9.6 ± 2.3 μm2; 24 h + 6 days: 6.7 ± 3.5 μm2; 24 h + 12 days: 6.8 ± 2.5 μm2) (g) also decline significantly over time (P < 0.001
already from 24 h to 24 h + 6 days). Aβ inclusions are marked with white arrow heads. Scale bars: 10 μm. The experiments were
performed in triplicates with independent cell cultures and 10 images/experiment were analyzed. Mann–Whitney U-test ***P < 0.001
Söllvander et al. Molecular Neurodegeneration  (2016) 11:38 Page 5 of 19
ingested material is only partially degraded within 12 days
(Fig. 3b). Neurons had low or no detectable Aβ42-555
inclusions at 24 h (Fig. 3c) whereas most of the few
oligodendrocytes in the culture contained large (+++) or
medium (++) Aβ42-555 inclusions that did not signifi-
cantly change over time (Fig. 3d). As a complement, we
next analyzed the total number of inclusions, total inten-
sity and total area of Aβ42-555 deposits (normalized to the
total number of cells) in the cell culture, using the Zen
2012 software. The number of 555-stained inclusions, nor-
malized to the number of live cell nuclei, declined signifi-
cantly from 24 h to 24 h + 6 days (P < 0.001), indicating
that the inclusions were either degraded or fused (Fig. 3e).
The total 555-intensity (Fig. 3f) and total 555-positive area
(Fig. 3g) also declined significantly over time (P < 0.001
already from 24 h to 24 h + 6 days), confirming that the
astrocytes degrade the Aβ42-555 protofibrils to some de-
gree, although very slowly. In contrast to our results with
Aβ42-555 protofibrils, cell cultures exposed to Aβ40-555
monomers, showed no accumulation of Aβ in astrocytes
(Additional file 8).
Engulfed Aβ protofibrils co-localize with the lysosomal
marker LAMP-1
In order to investigate the intracellular localization of the
Aβ deposits in astrocytes we next performed immunos-
tainings with the lysosome specific antibody LAMP-1.
Our results show that there was only little overlap be-
tween LAMP-1 and Aβ42 directly after the Aβ42 protofibril
exposure (24 h), but the co-localization increased over
time and 12 days after Aβ42 protofibril removal, most of
the intracellular Aβ42 deposits co-localized with LAMP-1
positive vesicles (Fig. 4a). These results demonstrate that
the engulfed Aβ42 protofibrils were transported to
lysosomal compartments within the astrocytes. However,
we have previously shown that engulfed dead cells in
astrocytes can be present in LAMP-1 positive phago-
somes/lysosomes without being degraded. The reason is
insufficient acidification of astrocytic lysosomes resulting
in inadequate digestion of the ingested material [26]. To
clarify if the lysosomes in the Aβ42 protofibril accumulating
astrocytes were acidic or not, we performed experiments
using LysoTracker, which is a dye that labels acidic organ-
elles. We found that although being LAMP-1 positive, the
Aβ42 containing lysosomes did not stain with the Lyso-
Tracker, indicating that Aβ42 stored in the glial cells were
situated in immature lysosomes (Fig. 4b). Interestingly,
immunostainings of brain sections from 14-month-old tg-
ArcSwe mice using specific antibodies against LAMP-2
and mAb158 (Fig. 4c) or GFAP and mAb158 (Fig. 4d)
demonstrated that Aβ co-localized with both LAMP-2
and GFAP in vivo. It was the outermost layer of the Aβ
plaque, rather than the plaque core that was LAMP-2 posi-
tive, suggesting that the most superficial Aβ could actually
be situated in lysosomal compartments inside the glial cells
that tightly surround the plaque (as GFAP only stains
15–20 % of the astrocytic cell bodies [36]).
Intracellular stored Aβ is truncated in the N-terminus
We next sought to investigate if the Aβ42 stored in the im-
mature lysosomes was partly degraded. For this purpose
we analyzed cell culture lysates using three different sets of
sandwich ELISAs; the N-terminus dependent Aβ1-x ELISA,
the protofibril specific mAb158 ELISA and the N-terminus
independent Aβx-42 ELISA. In the Aβ1-x ELISA, one of the
antibodies is specific for the N-terminal Aβ neo-epitope
(82E1, raised against Aβ1-16) and the other antibody binds
to the central region of Aβ (4G8, raised against Aβ17-24),
measuring Aβ42 with an intact N-terminal. In the Aβx-42
ELISA, one of the antibodies is specific for the C-terminal
Aβ42 neo-epitope [42] and the other antibody binds to the
central region of Aβ (4G8), measuring both intact and N-
terminally truncated forms of Aβ. Both the Aβ1-x ELISA
and the mAb158 ELISA, showed a 3-fold decrease in Aβ
concentrations from 24 h to 24 h + 6 days (P < 0.001 for
both) (Fig. 5a, b). The Aβ levels measured by the Aβ1-x
ELISA decreased further and were halved at 24 h + 12 days
compared to 24 h + 6 days (P = 0.0058) (Fig. 5a). In con-
trast, when analyzing the cell lysates using the Aβx-42
ELISA, the concentrations did not decrease during the first
6 days and there was only a 1.5-fold decline from 24 h +
6 days to 24 h + 12 days (P = 0.036). Hence, the concentra-
tions remained higher using the Aβx-42 ELISA compared to
the Aβ1-x and mAb158 ELISA, indicating that a high pro-
portion of the stored Aβ is N-terminally truncated
(Fig. 5a–c). Since our immunostainings demonstrated that
the engulfed Aβ often co-localized with condensed cell nu-
clei of dead cells that had also been ingested by the astro-
cytes (Fig. 1a), we performed additional analysis of the
pellet (consisting of nuclei and cell debris) that remained
after the cell lysis procedure. The pellets were treated with
formic acid and sonication to extract Aβ prior to analysis
with the Aβ1-x ELISA and the Aβx-42 ELISA. Interestingly,
we found that the pellet fraction from 24 h, but also from
24 h + 6 days and 24 h + 12 days showed higher Aβ con-
centrations in the Aβx-42 ELISA compared to the Aβ1-x
ELISA, indicating existence of N-terminally truncated Aβ42
(Fig. 5d, e). Taken together, the results show that full length
Aβ1-42 and Aβ42 protofibrils (Fig. 5a, b, d) decrease
more over time than N-terminally truncated forms of
Aβ (Fig. 5c, e), indicating that the intracellular deposits of
Aβ in astrocytes are processed by the astrocytes in a way
that may change their properties and toxicity.
Aβ accumulation induces formation of giant astrocytic
endosomes
The cell cultures were followed for up to 5 days after the
Aβ42 protofibril exposure, using time-lapse recordings.
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Interestingly, we found that the accumulation of Aβ42
protofibrils induced formation of enlarged, dynamic vac-
uoles in the astrocytes (Fig. 6a, and Additional file 9).
The vacuoles increased rapidly in size, fused with adja-
cent vacuoles and resulted in giant vacuoles with a
diameter of ~50 μm (Fig. 6b, and Additional file 10).
The giant vacuoles eventually shrank or collapsed, but
concurrently new vacuoles appeared in the same cell
(Fig. 6a, and Additional file 9). The enlarged vacuoles
were never found in control cultures, indicating that
they are a direct result of the high Aβ42 load in the
astrocytes. Immunostainings of fixed, Aβ42 protofibril
exposed cell cultures, using specific antibodies to the
early endosomal marker, Rab5, and the late endosomal
marker, Rab7, demonstrated that the giant vacuoles are
proposed to be derived from early endosomes (Fig. 6c).
Moreover, double stainings with specific antibodies to
Aβ/Rab5 and Aβ/Rab7 (Additional file 11), showed a
clear co-localization of Aβ inclusions and Rab5. Some
co-localization was also noted for Aβ and Rab7. These
data emphasize that accumulation of Aβ42 protofibrils
induces severe lysosome failure in the phagocytic
Fig. 4 Aβ42 accumulates in immature lysosomes. The co-localization of Aβ42 and LAMP-1 positive lysosomes increases from 24 h to 24 h + 12 days
(a). LysoTracker staining does not overlap with the Aβ42 protofibril inclusions, demonstrating that the Aβ42 containing lysosomes are immature
(b). Aβ42 protofibrils co-localize with LAMP-2 (c) and GFAP (d) in sections of 14-month-old tg-ArcSwe mice. Scale bars: a–d = 20 μm
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astrocytes. The collapsing vacuoles did not cause astro-
cytic cell death during the time-lapse experiment, but
may induce the release of Aβ containing microvesicles
from the astrocytes.
Engulfing astrocytes induce secondary Aβ toxicity
To further investigate how the Aβ42 protofibril exposure
affects viability of the three different cell types in the
culture, we quantified the number of living astrocytes,
neurons and oligodendrocytes directly after the 24 h
Aβ42 protofibril exposure and 6 and 12 days after Aβ42
protofibril removal. The total number of cells was com-
pared to the cell number in parallel control cultures that
did not receive any Aβ42 protofibrils. A modest, but sig-
nificant, increase in the cell number following Aβ42 pro-
tofibril exposure was noted at 24 h + 12 days, for both
astrocytes and oligodendrocytes (P = 0.011 and P < 0.001,
respectively) (Fig. 7a and b), indicating that the Aβ42
protofibril clearing process induces some proliferation of
the glial cells. In contrast, the number of neurons was
decreasing over time in the Aβ42 protofibril exposed cul-
tures (Fig. 7c). The fact that Aβ42 protofibril exposure
did not induce neuronal death directly, but the decrease
in neuronal number appeared 12 days after Aβ42 protofi-
bril removal (P = 0.0061), indicates that the cell death is
due to a secondary mechanism.
Neuronal cell death is induced by secreted microvesicles
To identify possible mechanisms for the secondary
toxicity, we investigated if microvesicles secreted by
Aβ42 protofibril treated co-cultures induce apoptosis of
cortical neurons. For these experiments we exposed co-
cultures with Aβ42 protofibrils for 24 h, washed the
cultures thoroughly and cultured the cells in Aβ42
protofibril-free medium for additional 12 days. Parallel
control cultures received medium only. Microvesicles
were isolated using ultracentrifugation of conditioned
medium harvested day 6 and 12 following Aβ42 protofi-
bril removal. The microvesicle pellets were reconstituted
in neurobasal medium and added to embryonic cortical
mouse neurons that had been cultured for 12 days
(12 days in vitro). After 48 h, the neurons were fixed
and the number of apoptotic, TUNEL labeled neurons
was compared (Fig. 8a). Studies of astrocytes using elec-
tron microscopy, demonstrated a release of microvesicles
of different sizes (Fig. 8b). Moreover, electron microscopy
analysis of the microvesicle preparations, identified micro-
vesicles (>100 nm in diameter, Fig. 8c–d). Microvesicles,
isolated from both untreated and Aβ42 protofibril exposed
cell cultures, expressed the microvesicle marker Flotillin-1.
However, no differences in the total protein concentration
of Flotillin-1 was detected between untreated and Aβ42
protofibril exposed cell cultures (Fig. 8e). Interestingly,
Fig. 5 Intracellular stored Aβ42 is truncated in the N-terminus. Aβ ELISAs of cell lysates from 24 h and from 6 to 12 days following Aβ42 protofibril
removal (24 h + 6 days and 24 h + 12 days, respectively) demonstrate that a high proportion of the accumulated Aβ is N-terminally truncated. The
concentrations of Aβ1-x (a) and Aβ protofibrils (b) decrease continuously from 24 h (2434.0 ± 272.0 and 946.9 ± 36.5, respectively) to 24 h + 6 days
(862.8 ± 92.0 and 325.8 ± 25.9, respectively) and 24 h + 12 days (468.2 ± 52.2 and 282.9 ± 13.1, respectively), while the concentrations of Aβx-42 remain
higher over time (24 h: 2475.0 ± 134.0, 24 h + 6 days: 226.01 ± 318.3 and 24 h + 12 days: 1531.0 ± 253.1) (c). In the pellets, remaining after the cell lysis
procedure, the Aβ1-x concentrations decline over time (24 h: 1840.0 ± 289.5, 24 h + 6 days: 938.3 ± 159.7, 24 h + 12 days: 483.3 ± 225.3) (d), while the
Aβx-42 concentrations are higher at 24 h (2422.0 ± 387.0) and more stable over time, 24 h + 6 days (1493.0 ± 132.7) and 24 h + 12 days (1488.0 ± 312.6)
(e). All concentrations are expressed in picomolar (pM) units. Mean values are from duplicates of three independent experiments
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there was a significant increase in apoptotic neurons in
cultures treated with microvesicles from Aβ42 protofibril
exposed co-cultures compared to controls (Fig. 8f),
demonstrating that Aβ42 protofibril accumulation induces
secretion of microvesicles with toxic content. Parallel neur-
onal cultures, exposed to intact Aβ42 protofibrils, directly
added to the medium, showed no difference in the per-
centage of TUNEL positive cell nuclei or the total number
of cell nuclei, compared to untreated cultures (Additional
file 12). Since the amount of microvesicles was unchanged
(based on the Flotillin-1 expression), the apoptotic effect
on neurons was due to the content of the microvesicles.
Aβ1-x and Aβx-42 ELISA analysis of microvesicles isolated
from the cell culture medium demonstrate that the micro-
vesicles contained primarily an N-terminally truncated
form of Aβ42 (Fig. 8g).
Fig. 6 Aβ42 protofibril treatment results in formation of enlarged endosomes. Time-lapse experiments demonstrate that Aβ42 protofibril treatment
induces the formation of enlarged, dynamic vacuoles (*) in the astrocytes (a). The enlarged vacuoles fuse (white arrow heads) with adjacent
vacuoles; forming giant vacuoles with a diameter of 30–50 μm (b). Immunocytochemistry show that the vacuoles express the early endosome
marker Rab5 and to a lesser extent the late endosome marker Rab7 (c). Inset in left corner of image c shows higher magnification of relevant
structure. Scale bars: a–b = 10 μm, c = 20 μm
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Discussion
Many studies indicate that the widespread neuronal dys-
function in the AD brain is caused by soluble Aβ aggre-
gates, such as protofibrils, rather than the insoluble
fibrils [8–13]. The mechanisms by which Aβ42 protofi-
brils induce neuronal toxicity is however unclear. It has
been suggested that Aβ oligomers promote neuronal cell
death, inhibit long-term potentiation and impair synaptic
function and plasticity [8, 9, 11, 12, 43–46]. In the
present study we show, by using a co-culture system of
neurons and glia, that Aβ42 protofibrils are not directly,
but indirectly neurotoxic. Extensive engulfment of Aβ42
protofibrils by the astrocytes in the co-culture results in
long-term intracellular deposits of Aβ, severe lysosomal
dysfunction and formation of N-terminally truncated Aβ
that is spread in the co-culture by microvesicle secretion.
Accumulation of Aβ in the AD brain is due to an im-
balance between the Aβ production and Aβ clearance.
Several studies indicate that monomeric Aβ40 and Aβ42
are degraded by cultured astrocytes following ingestion
[47–49]. This conclusion was based on observations that
the engulfed Aβ was directly transported to LAMP-
positive lysosomes following ingestion [47, 49, 50]. How-
ever, neither of the studies confirmed if Aβ degradation
actually took place in the lysosomes. We hypothesized
that aggregated species of Aβ, such as protofibrils, may
be more difficult for the cells to handle than the mono-
meric form of the protein. Our results show that the
degradation of Aβ42 protofibrils in astrocytes is indeed
extremely slow, although the ingested Aβ is situated in
LAMP-1 phagosomes/lysosomes. Instead, the Aβ42 pro-
tofibrils accumulate in the astrocytes, leading to large,
intracellular inclusions. In contrast to Aβ42 protofibrils,
Aβ40 monomers were not accumulated in the astrocytes,
indicating that they are not overall slow degraders. We
have previously compared phagocytosis of dead cells by
astrocytes and macrophages (which are indistinguishable
from activated microglia in the pathological brain) and
found that astrocytes in contrast to the professional
phagocytes store, rather than degrade ingested dead cells
[26, 30]. By using the pHrodo-labeling technique we
demonstrated that material ingested by macrophages
fuses with mature/acidic lysosomes within 5 h, whereas
material engulfed by astrocytes still had not fused with
acidic lysosomes after 3 days. Thus, astrocytes are inef-
fective when it comes to degrading large/toxic material
such as cell corpses and protein aggregates. Some reports
indicate that astrocytes may be more efficient than micro-
glia in taking up Aβ, particularly during the early stages of
AD and astrocytes has been shown to gradually accumu-
late Aβ throughout cortex in AD patients [28, 29, 51–53].
However, the difference in degradation capacity of the two
cell types has not been taken in account in these studies.
Our data show that glial cells, but not neurons accu-
mulate Aβ42 protofibrils. Since the glial cells in our dif-
ferentiated co-culture system do not die following Aβ
exposure, it is unlikely that the noted co-localization of
Aβ and dead nuclei is due to phagocytosis of dead Aβ
containing cells. Dead cells are however constantly
ingested by the astrocytes during the differentiation
process, when apoptosis is naturally occurring. These dead
cells are then stored in the astrocytes for weeks. Hence,
the co-localization is probably due to transportation of the
ingested material to the same “garbage dumps” within the
astrocytes. Moreover, the ingestion of Aβ is very rapid.
Our time-lapse experiments demonstrated that intracellu-
lar Aβ-555 deposits are visible already after 30 min
(Fig. 2a). Over time the 555-signal of these deposits
Fig. 7 Aβ42 protofibril treatment induces secondary neuronal cell death. The number of astrocytes in Aβ42 protofibril exposed cultures is significantly
increased from 24 h (1.0 ± 0.1) to 24 h + 12 days (1.1 ± 0.1, P = 0.011) (a). Similar to astrocytes, the number of oligodendrocytes increases from 24 h
(0.7 ± 0.3) to 24 h + 12 days (1.7 ± 1.5, P < 0.001) in Aβ42 protofibril treated cultures (b). Aβ42 protofibril treatment has no direct effect on neurons, but
the neuronal cell number significantly decreases (from both 24 h, 0.9 ± 0.4, P= 0.0061 and 24 h + 6 days, 1.0 ± 0.4, P = 0.0083) in the treated cultures
12 days (0.7 ± 0.5) after Aβ removal (c). The relative number of viable cells in Aβ42 protofibril exposed cultures is normalized to viable cells in unexposed
cultures. The experiments were performed in triplicates with independent cell cultures and 10 images/experiment were analyzed. Mann–Whitney
U-test ***P < 0.001
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becomes more and more intense, indicating that the Aβ
aggregates are constantly engulfed by the astrocytes and
then transported to specific sites within the astrocytes.
In an attempt to identify reasons for the slow digestion
of engulfed dead cells in primary astrocytes, we previ-
ously found that actin rings surround the phagosomes
for long periods of time, which physically inhibit the
phago-lysosome fusion [30]. Furthermore, astrocytes ex-
press high levels of Rab27a, a protein known to reduce
the acidity of lysosomes by Nox2 recruitment, in order
to preserve antigens for presentation. We demonstrated
that Nox2 co-localizes with the ingested material,
indicating that it may influence antigen processing also
in astrocytes, as they express MHC class II [30]. By
Fig. 8 Neuronal cell death is induced by secreted microvesicles. Illustration of the experimental setup (a). Electron microscopy images of Aβ42
protofibril exposed co-cultures demonstrate microvesicle (*) secretion from a single astrocyte (b) and a larger (c) and smaller (d) microvesicle
present in the cell culture medium. Western blot analysis show that the isolated microvesicles express Flotillin-1, but that the levels are unchanged in Aβ42
protofibril treated cultures, compared to controls (e). TUNEL assays demonstrate a significant increase (P< 0.001) in apoptotic neurons following treatment
with microvesicles from Aβ42 protofibril exposed co-cultures (465.4 ± 150.4), compared to microvesicles from untreated co-cultures (308.3 ± 109.2) (f).
The experiments were performed in triplicates with independent cell cultures and 10 images/experiment were analyzed. Microvesicles isolated from
medium collected 6 and 12 days after Aβ42 protofibril exposure contain Aβ as revealed in Aβ1-x (396.9 ± 167.2 pM) and Aβx-42 (1239.0 ± 438.7 pM)
ELISA. The Aβ1-x concentration is lower than Aβx-42, indicating that there is a truncation of the Aβ42 N-terminus (g). Duplicate samples
from 3 independent experiments were analyzed. Mann–Whitney U-test ***P < 0.001. Scale bars: b = 1 μm, c–d = 100 nm
Söllvander et al. Molecular Neurodegeneration  (2016) 11:38 Page 11 of 19
inducing long-time acidification of astrocytic lysosomes
using acidic nanoparticles, we could increase the diges-
tion of astrocyte-ingested dead cells. The degradation
was, however, normalized over time, indicating that in-
hibitory pathways are up-regulated in response to the
enhanced acidification [30]. By staining the cell cultures
with LysoTracker dye in the present study, we also
found the lysosomes to be of low acidity, which probably
contributes to the incomplete digestion of Aβ. Moreover,
the deposition of aggregated Aβ42 in astrocytes results in
severe lysosomal dysfunction, including formation of
enormous endosomes, indicating that the accumulation
of Aβ disturbs the endosome/lysosome machinery. Such
enlarged endosomes were never observed in astrocytes
storing cell corpses, or cultures exposed to Aβ40 mono-
mers, but only in Aβ42 protofibril accumulating astro-
cytes. It is likely that this toxic effect of Aβ42 protofibrils
affects the astrocytes so that their slow degradation is
further reduced.
The fact that the Aβ42 deposits in astrocytes co-
localize with the lysosomal marker LAMP-1 indicates
that the lysosome function is crucial for Aβ degradation.
It is however not excluded that other degradation mech-
anisms, such as the proteasome machinery could be af-
fected by the presence of toxic Aβ aggregates in the cell.
Sections of tg-ArcSwe mice revealed that the Aβ plaques
were surrounded by LAMP-2 immunoreactive astro-
cytes. These findings agree with previous reports of
increased LAMP-1 in cerebral cortex of AD patients as
the disease progresses [54] and in brains of APPSL-Tg
mice during aging [55]. Interestingly, it has been demon-
strated that activation of transcription factor EB (TFEB),
a regulator of lysosome biogenesis, enhanced uptake and
degradation of Aβ in astrocytes, attenuating plaque path-
ology in APP/PS1 transgenic mice [49]. By studying the
lysosomal storage disorder, multiple sulfatase deficiency
(MSD), it has been suggested that normal autophagic,
endocytic, and lysosomal vesicle trafficking is essential
for preventing neurodegeneration [56]. One of the
earliest pathological signs observed in patients with AD
is the accumulation of numerous enlarged autophagic
and endosomal vesicles, due to defective autophagy-
lysosomal degradation in neurons [33, 57, 58]. The
defect may result from impaired vesicle fusion among
autophagosomes, endosomes and lysosomes [34, 57, 59,
60] or failure of lysosomal acidification [61]. Aβ42 has
been shown to induce autophagy and lysosomal degrad-
ation dysfunctions which may lead to indigestible Aβ
storage inside the vesicles [62, 63].
The accumulated Aβ in the astrocytes was partly
modified to N-terminally truncated Aβ. The absence of
the full Aβ N-terminus may thereby, to some extent,
underestimate the intracellular Aβ concentration when
analyzing cell lysate with the N-terminus dependent
Aβ1-x and Aβ protofibril ELISA. N-terminally truncated
Aβ, often bearing amino-terminal Glu3 which eventually
modifies to pyroglutamate (AβN3pE-x), is found both in
extracellular, intracellular and vascular deposits in AD
and Down's syndrome brain tissue [64]. Astrocytes have
been implied to take up N-terminally truncated Aβ from
fleecy amyloid in AD brains and diffuse plaques from
non-demented individuals [65, 66]. As we exposed astro-
cytes with full length Aβ42 in the protofibrillar form, we
propose that the truncation of Aβ in fact might occur by
the endosomal/lysosomal pathway in the astrocytes.
Since the N-terminals are sticking out from the Aβ
protofibrils, they are easily accessible, compared to the
C-terminals that are hidden in the core of the aggregate.
We suggest that since the astrocytes degradation system is
ineffective, degradation is not completed and partly de-
graded (N-terminally truncated) Aβ is left. N-terminally
truncated Aβ has been found to be more resistant to deg-
radation, more prone to aggregate and more toxic than
full - length Aβ [67]. Our hypothesis is that astrocytes try
to be “helpful”, but are overwhelmed by the difficulties
they face. Hence, they cannot fulfill their task to degrade
the Aβ protofibrils, and instead of being “helpful” they
promote spreading of the Aβ pathology, by secreting Aβ
aggregates that had been only partly degraded. In the AD
brain, reactive astrocytes are attracted to the Aβ plaques
and are highly exposed to various forms of Aβ aggregates.
Engulfment of Aβ by astrocytes may initially be a protect-
ive clearance mechanism, but based on our data, overbur-
den of the astrocytes is clearly detrimental.
Astrocytes are highly responsible for maintaining brain
homeostasis and although our results show that the high
Aβ load does not induce apoptosis in astrocytes, their
normal functions are probably severely affected. Miscon-
duct in the performance of astrocytes normal responsi-
bilities would affect processes such as metabolic support
of neurons, modification of synapse signaling, recycling
of neurotransmittors, regulation of blood flow and func-
tion of the blood brain barrier [2, 3].
The way in which Aβ pathology spreads in the AD
brain has been debated for many years. Experimental
evidence suggests that amyloid proteins, such as Aβ, in-
deed can seed and transmit pathology in the brain. For
example, it has been shown that injection of cortical ex-
tracts from post-mortem AD brains into the brains of
transgenic APP mice, aggravates plaque pathology within
five months [68] and longer incubation also induces tau
pathology [69]. The cellular mechanism behind the
spreading of AD pathology is still unclear, but both cell-
to-cell transmission [70] and secretion into the extracellu-
lar space [71] have been suggested as possible pathways.
Ineffective degradation of Aβ may lead to spreading of AD
pathology, due to secretion of Aβ containing microvesicles
[35, 72]. Interestingly, Aβ peptides have been found to be
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released from AβPP transfected neuroblastoma cells via
exosomes. Moreover, the exosome specific proteins Alix
and Flotillin-1, have been found around plaques in human
AD brains and within senile plaques of Tg2756 mice,
respectively [72, 73]. We have previously shown that
astrocytes express high levels of proteins known to
promote vesicle secretion [26, 30, 74, 75]. In contrast
to neurons, which mainly secrete Aβ beginning at Asp1,
the majority of Aβ secreted from glial cells has proven to
be N-terminally truncated [76].
Conclusion
In conclusion, we demonstrate that astrocytes engulf large
amounts of protofibrillar Aβ42 that are only partly digested
and stored in the cells for very long times. The intracellular
Aβ accumulation results in severe astrocytic endosome/
lysosome defects and microvesicle-induced neurotoxicity.
In familial AD, with mutations in the AβPP, Presenilin 1 or
Presenilin 2 genes, increased Aβ production or increased
Aβ42/Aβ40 ratio lead to AD. However, in sporadic AD it is
likely that defective Aβ clearance is the culprit. Thus, accu-
mulation of Aβ in astrocytes could play a vital role in the
sporadic form of the disease and a better understanding of




Fluorescent HiLyte™ Fluor 555-labeled Aβ42 (Aβ42-555)
peptides (Anaspec Inc) were diluted in 10 x phosphate
buffered saline (PBS) to a concentration of 36 μM
followed by incubation for 4 h at 37 °C. Synthetic Aβ42
peptides (American Peptide Company Inc.) were prepared
as previously described [13, 77–79]. Aβ42 dissolved in
10 mM NaOH was mixed with 10 x PBS to 443 μM
(2 mg/ml) and incubated 30 min at 37 °C. Both Aβ42-555
protofibrils and unlabeled Aβ42 protofibrils were centri-
fuged for 5 min at 17 900 x g to remove any insoluble ag-
gregates. Using the protofibril specific ELISA, mAb158
[41], we concluded that we had the best yield of Aβ42-555
protofibrils after 4 h incubation in 37 °C. Aβ42-555 proto-
fibrils were readily detected by mAb158 ELISA and there
was no significant difference between 555-labeled and un-
labeled Aβ42 protofibrils (Additional file 13). To estimate
the purity (>95 %) and size of the Aβ42 protofibrils, 50 μl
of 250 μg/ml Aβ42 protofibrils were analyzed by size-
exclusion chromatography (SEC) using a Superdex 75 col-
umn. The Aβ42 protofibrils (>95 % purity) eluted in the
void volume and was estimated to be >75 kDa based on
the cutoff size of the Superdex column (Fig. 9).
Animals
All experiments involving animals were performed at
Uppsala University, Sweden. The experiments were
approved by the Uppsala County Animal Ethics Board
(ethical permit number: C75/13, valid 2013-06-28 to
2018-06-28), following the rules and regulations of the
Swedish Animal Welfare Agency, in compliance with the
European Communities Council Directive of 22 September
2010 (2010/63/EU). C57/BL6 mice were used for cell cul-
ture studies and tg-ArcSwe mice, harboring the human
Arctic (E693G) and Swedish (KM670/671NL) AβPP muta-
tions (Lord 2007) for in vivo experiments. The animals
were housed at the National Veterinary Institute, Uppsala
or the animal facility at Uppsala University Hospital,
Uppsala in a 12-12 dark-light cycle. The mice were kept in
an enriched environment and given water and food ad
libitum.
Neural cell cultures
Cerebral cortices from C57/BL6 mice of embryonal day
14 (E14) were dissected in Hank’s buffered salt solution
supplemented with 50 U/ml Penicillin, 50 mg/ml
Streptomycin and 8 mM Hepes buffer (HBSS, all from
Invitrogen). The cortices were dissociated in fresh HBSS,
centrifuged at 150 x g and resuspended in cell culture
medium.
Co-cultures of neurons and glia
According to Loov et al. [30], the cells were expanded in
DMEM/F12-GlutaMAX supplemented with 1 x B27, 50
U/ml Penicillin, 50 mg/ml Streptomycin and 8 mM
Hepes buffer, 10 ng/ml bFGF (all from Invitrogen) and
20 mg/ml EGF (VWR). Neurospheres were passaged
every second or third day by dissociation in HBSS and
resuspended in medium with bFGF and EGF. Prior to
experiments, the cells were plated as a monolayer, at
a concentration of 1.5 × 105 cells/ml, on cover slips
(In Vitro Diagnostics) or cell culture dishes (Falcon),
coated with Poly-L-Ornithine (Sigma-Aldrich) and Laminin
(Invitrogen). After 24 h, the medium was replaced with
mitogen-free medium to initiate neural stem cell dif-
ferentiation to a mixed population of neurons, astrocytes
and oligodendrocytes, but not microglia. This is a well char-
acterized cell culture system, based on the lineage restricted
differentiation of embryonic, cortical stem cells [38, 80, 81].
To drive the differentiation towards generation of exclu-
sively astrocytes, 10 ng/ml cilliary neurotrophic factor
(CNTF) was added to the mitogen-free medium through-
out the differentiation process [37, 38]. During the seven
days differentiation period, the cell culture medium was
changed every second or third day. Only neurospheres
from passage 2–4 were used for experiments.
Neuronal cultures
Following dissection and dissociation the cells were
seeded on Poly-L-Ornithine and Laminin coated cover
slips at a concentration of 8 × 104 cells/ml. The neurons
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were cultured in neurobasal medium supplemented with
1 x B27, 50 U/ml Penicillin, 50 mg/ml Streptomycin and
20 mM L-glutamine (Invitrogen) for 12 days (12 DIV)
prior to experiment. The first day after seeding, the cell
culture medium was fully replaced followed by changing
half of the medium every second or third day.
Aβ stimulation
Cell cultures differentiated into neurons and glia or as-
trocytes and pure neuronal cultures were treated with
0.1 μM Aβ42 protofibrils (either 555-labeled or un-
labeled) for 24 h. Controls received fresh cell culture
medium without Aβ42 protofibrils. After Aβ treatment,
the cells were washed in cell culture media x 3 and the
cover slips were transferred to new culture dishes. The
cells were fixed, lysed (24 h) or cultured for additional 6
(24 h + 6 days) or 12 days (24 h + 12 days) in Aβ free -
cell culture medium prior to fixation or cell lysis.
Microvesicles
Co-cultures of neurons and glia were treated with
0.1 μM Aβ42 protofibrils for 24 h or left untreated. The
cultures were thoroughly washed x 3 and were continu-
ously cultured in medium only. From day 6 to day 12
following Aβ42 protofibril treatment, the medium was
harvested and centrifuged for 5 min at 300 x g to re-
move any cell remnants. For microvesicle preparations
(containing exosomes and larger vesicles), the superna-
tants were centrifuged for 10 min at 2000 x g to remove
apoptotic bodies followed by ultracentrifugation for
1.5 h at 4 °C at 135 000 x g. The ultracentrifugation was
performed in Ultra-Clear centrifuge tubes (Beckman
Coulter) using a Beckman LE-80 ultracentrifuge. For the
neurotoxicity assays, the pellets containing microvesicles
were reconstituted in neurobasal medium supplemented
with 1 x B27, Penicillin and Streptomycin and L-glutamine
(Invitrogen) and added to cortical neurons. After 48 h, the
neuronal cultures were fixed and the number of apoptotic
cells quantified. Parallel control cultures were exposed to
0.1 μM Aβ42 protofibrils or left untreated for 48 h prior to
fixation. For analysis of the Aβ content, the isolated
microvesicles were lysed in ice cold lysis buffer (20 mM
Tris pH 7.5, 0.5 % Triton X-100, 0.5 % deoxycholic acid,
150 mM NaCl, 10 mM EDTA, 30 mM NaPyroP and pro-
tease inhibitor (Roche)) and stored in −70 °C until time of
analysis by ELISA.
Immunostaining of cell cultures
Cover slips were fixed for 15 min in RT with 4 % parafor-
maldehyde and permeabilized and blocked with 0.1 % Tri-
ton X-100 (both from Sigma-Aldrich) and 5 % normal goat
serum (NGS, Bionordica) in PBS for 30 min in RT. Primary
antibodies were incubated in 0.1 % Triton X-100 with
0.5 % NGS for 1–4 h in RT or O/N in 4 °C. Thereafter,
cover slips were washed thoroughly in PBS x 3 between
each step. Incubation with secondary antibodies was per-
formed in 0.1 % Triton X-100 and 0.5 % NGS for 45 min
in 37 °C or 1 h in RT. The following primary antibodies
were used in the study: rabbit anti-Glial Fibrillary Acidic
Protein (GFAP, 1:400, DakoCytomation), mouse anti-GFAP
(1:400, Sigma-Aldrich), mouse anti-2',3'-Cyclic-nucleotide
3'-phosphodiesterase (CNPase, 1:500, Sigma-Aldrich),
mouse anti-βIII tubulin (1:200, Covance), rabbit anti-
Lysosome-associated membrane protein-1 (LAMP-1,
1:200, Abcam), rabbit anti-Rab5 (1:1000, Abcam), mouse
anti-Rab7 (1:1000, Abcam), polyclonal rabbit anti-Aβ42
(1:200, Invitrogen), monoclonal mouse anti-Aβ antibody,
6E10 (10 μg/ml, epitope: 3-8, Signet), the monoclonal
mouse anti-Aβ antibody, mAb1C3 (10 μg/ml, epitope: 3-
8) [41] and monoclonal mouse anti-Aβ protofibril select-
ive antibody, mAb158 (10 μg/ml) [41]. Secondary anti-
bodies used were: AlexaFluor 488, 555 and 647, all against
mouse or rabbit (1:200, Molecular probes). To study
acidic lysosomes, 0.5 μM LysoTracker red DND-99 (Ther-
moFisher) was added to the cell culture medium 2 h prior
to fixation. Neuronal apoptosis was measured using ter-
minal (TdT)-mediated dUTP-biotin reaction mixture
(TUNEL, Roche Biochemicals) according to the manufac-
turer’s instructions. The cover slips were mounted on
microscope glass slides using vectashield hard set mount-
ing medium with DAPI (DAKO). A Zeiss Observer Z1
Microscope and Carl Zeiss LSM700 confocal microscope
Fig. 9 Aβ42 protofibril characterization. A chromatogram following Aβ42 protofibril analysis by SEC using a Superdex 75 column. The chromatograms
show mV for the absorbance at 214 nm on the y-axis and the retention time in minutes on the x-axis
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(Zeiss) were used for analysis. Images and confocal
z-stacks were visualized with Zen 2012 software.
Time-lapse experiments
Time-lapse experiments were performed at 37 °C in
humidified 5 % CO2 in air, using a Nikon Biostation IM
Live Cell Recorder (Nikon). The cells were cultured at a
concentration of 1.5 × 105 cells/ml, in time-lapse culture
dishes (VWR) and pictures were taken every 10th minute
for up to 5 days.
Transmission electron microscopy
Cells
Cells were briefly washed in PBS prior to fixation in 2.5 %
glutaraldehyde (1 h or O/N in 4 °C). The dishes containing
the cells were rinsed in 0.15 M Na-caccodylate and incu-
bated for 1 h in 1 % osmium tetroxide in Na-caccodylate
at RT followed by Na-caccodylate rinse. Dehydration was
performed with 70 % ethanol for 30 min, 95 % ethanol for
30 min and 99.7 % ethanol for 1 h. A thin layer of newly
made plastic (Agar 100 resin kit, Agar Scientific Ltd) was
added for 1 h to permit evaporation of the alcohol. The
plastic was poured off and a second plastic layer was added
and left O/N in a desiccator. Next, plastic was heated up in
an oven to enable its removal and a thicker, newly made
plastic layer was added. The dishes were incubated in des-
iccator for 1–4 h before polymerization in oven (60 °C) for
48 h. Cells were sectioned using Leica ultracut UTC ultro-
tome (Rowaco AB) and studied in a Tecnai G2 transmis-
sion electron microscope (FEI Company). ORIUS SC200
CCD was used as camera and Gatan Digital Micrograph as
software (both Gatan Inc.).
Microvesicles
Microvesicles were isolated by ultracentrifugation as de-
scribed above and reconstituted in PBS. Samples were
added onto a formvar-coated 200-mesh grid (Oxford
Instruments) and incubated for 45 min in RT. The grid
was dried and 1 % uranyl acetate was added for 10 s.
Before analysis in a Tecnai G2 transmission electron
microscope (FEI Company), the grid was dried for at least
15 min. ORIUS SC200 CCD was used as camera and
Gatan Digital Micrograph as software (both Gatan Inc.).
Cell lysates
For Aβ quantification studies, co-cultures of neurons and
glia were seeded out in a concentration of 2.4 × 105 cells/ml
in 60 mm x 15 mm cell culture dishes (Corning). Follow-
ing removal of the cell culture medium, 100 μl ice cold
lysis buffer (20 mM Tris pH 7.5, 0.5 % Triton X-100, 0.5 %
deoxycholic acid, 150 mM NaCl, 10 mM EDTA, 30 mM
NaPyroPand protease inhibitor, Roche) was added to the
dish. The lysed cells were collected using a cell lifter
(Costar), transferred to Eppendorf tubes, incubated on ice
for 30 min and centrifuged (30 min, 4 °C, 12 000 x g). The
supernatant was collected and the remaining pellet was
dissolved in 50 % formic acid and sonicated in 4 × 4 s
pulses for 30 effective seconds at 50 % amplitude. Both
the supernatants and pellets were stored in −70 °C until
time of analysis by ELISA.
Aβ1-x and Aβx-42 ELISAs
For Aβ1-x ELISA [82] ninety-six well EIA/RIA plates
(Corning Inc.) were coated O/N at 4 °C with the N-
terminus (epitope 1-5) antibody mAb82E1 (100 ng/well,
IBL-Hamburg) in PBS. Plates were blocked with 1 %
bovine serum albumin (BSA) in PBS for 2 h in RT.
Standard series of synthetic Aβ42 monomers (American
Peptide) and samples (all except pellets of the lysates)
were denatured by boiling for 5 min in 0.5 % sodium do-
decyl sulfate (SDS) to avoid impaired detection caused
by aggregated Aβ [83]. Before addition to plates, all SDS
treated samples were diluted x 10 to decrease the SDS
concentration and incubation followed for 2 h. Biotinyl-
ated mAb4G8 (0.3 μg/ml, Covance), specific for the mid
region of Aβ, was used as secondary antibody and incu-
bated for 1 h followed by incubation with streptavidin
coupled HRP (1:2000, Mabtech AB) for 1 h. K-blue en-
hanced (Neogen Corporation) was used as HRP sub-
strate and the reaction was stopped with 1 M H2SO4.
Plates were measured by Tecan Infinite M200 PRO
spectrophotometer (Tecan Group Ltd.) at 450 nm and
analyzed with Magellan v7.0 software (Tecan Group
Ltd.). Washing was performed by adding 250 μl washing
buffer (phosphate buffered NaCl with 0.1 % Tween 20
and 0.15 % Kathon) x 3 repetitions between each step of
the ELISA. All dilutions occurred in ELISA incubation
buffer (0.05 % Tween, 0.1 % BSA and 0.15 % Kathon in
PBS at pH 7.4). For the Aβx-42 ELISA, polyclonal
Aβ42 antibody (100 ng/well, Agrisera) and biotinylated
mAb4G8 (0.5 μg/ml) was used as primary and secondary
antibody, respectively. Aβx-42 ELISA [13] was performed
according to the same protocol as the Aβ1-x ELISA, except
for prolonged incubation times for blocking, sample (both
O/N, 4 °C) and secondary antibody (2 h, RT) and in-
creased SA-HRP dilution (1:5000). The pellet samples
were neutralized with 1 M Trizma base + 0.5 M Na2HPO4
prior to the ELISA analysis.
Aβ protofibril ELISA
Aβ protofibril ELISA using mAb158, was performed ac-
cording to the protocol described by Englund et al. [41].
In short, ninety-six well EIA/RIA plates (Corning Inc.)
were coated with 200 ng/well of mAb158 in 100 μl PBS
at 4 °C O/N. Plates were blocked with 1 % BSA in PBS
with 0.15 % Kathon. Standard series of synthetic Aβ42
protofibrils and samples were added to the plates for 2 h
incubation in RT. All dilutions occurred in ELISA
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incubation buffer. After washing the plate, 0.5 μg/ml of
biotinylated mAb158 was added and incubated for 1 h in
RT. Subsequent steps and washing steps were performed
as previously described in the Aβ1-xELISA method.
Immunostaining of mouse brain tissue
Twelve-fourteen-month-old tg-ArcSwe mice were per-
fused with isotonic saline solution followed by 4 %
phosphate-buffered formaldehyde (Histolab AB). The
brains were frozen and cryo-sectioned sagittally to a thick-
ness of 14 μm and then permeabilized and blocked in
0.3 % Triton X-100 in PBS containing 5 % NGS for 1 h in
RT. The sections were incubated at 4 °C O/N with pri-
mary antibody diluted in 0.3 % Triton/PBS with 0.5 %
NGS and thoroughly washed in 0.3 % Triton/PBS. There-
after, sections were incubated for 1 h in RT with second-
ary antibody diluted in 0.3 % Triton/PBS with 0.5 % NGS
before repeating the washing step. The sections were
mounted on microscope glass slides with Vectashield con-
taining DAPI (Vector). Primary antibodies used were:
rabbit anti-GFAP (1:400, DakoCytomation), mouse anti-
GFAP (1:500, Sigma), rat anti-LAMP-2 (1:400, Abcam)
and mAb158 (5 μg/ml). Secondary antibodies used
were AlexaFluor 488 against mouse, rabbit and rat or
AlexaFluor 555 against mouse and rabbit (1:500,
Molecular probes).
Western blot analysis
Microvesicle lysates were prepared as described above.
26 μl of each sample was loaded to a 4–12 % Bis-Tris Gel
(NuPAGE, Life Technologies). Novex® Sharp Standard
(Life technologies) was used as a standard. The gel was
run for 1 h at 175 V in MES buffer (NuPage, Life Tech-
nologies) followed by transfer for 1 h at 20 V onto a PVDF
membrane (Invitrogen). The membrane was blocked with
5 % BSA in TBS with 0.2 % Tween (TBS-T) for 1 h (RT),
followed by washes in TBS-T and incubation with
Flotillin-1 (mouse monoclonal, 1:500, BD Biosciences)
antibody in 0.5 % BSA in TBS-T over night (4 °C). After
extensive washes in TBS-T the membrane was incubated
with a peroxidase-conjugated goat anti-mouse IgG (1:20
000, Pierce) antibody in 0.5 % BSA in TBS-T for 1 h (RT)
and then finally washed again in TBS-T. The enhanced
chemiluminescence (ECL) system (GE Healthcare) was
used for development.
Aβ inclusions, area, intensity measures and cell counting
Thirty images (10 images/cover slip from three independ-
ent cultures) were captured with an x40 objective on a
Zeiss Observer Z1, using exactly the same settings. For
the co-localization studies the images were manually ana-
lyzed. The cells were divided into four categories; cells
with no detectable levels of Aβ42-555 protofibrils (−), cells
with only small amounts of Aβ42-555 protofibrils (+), cells
containing medium amounts (a couple of small Aβ42-555
protofibril inclusions or larger Aβ42 protofibril inclusions
with low intensity of the 555-staining) (++) and cells with
one or more large Aβ42-555 protofibril inclusions (+++).
For Aβ intensity and area measurements, the images were
analyzed with the Zen 2012 software (Zeiss). All area and
intensity measurements of Aβ were set manually in the
software and the number of viable cells was determined
by manually counting cell nuclei in each field. Due to low
cell numbers, the x20 objective was used when counting
the number of viable neurons and oligodendrocytes. All
images were analyzed in a blinded fashion.
Statistics
All experiments were performed in triplicates with inde-
pendent cell cultures derived from embryos of different
pregnant mice. The results are presented in scatter plots
or box plots with mean +/− standard deviation. Since
the data was found not to meet the assumption of
normal distribution, using the Shapiro-Wilk’s W-test,
unpaired t-test and Kruskal-Wallis ANOVA, followed by
Mann–Whitney U-test for pair-wise comparisons was
used. Level of significance were set to *P < 0.05, ** < 0.01
and *** < 0.001.
Additional files
Additional file 1: Aβ42 protofibril deposits are found in astrocytes,
but not in neurons. Co-cultures stained for astrocytes (GFAP), neurons
(βIII-tubulin) and Aβ42-555 protofibrils demonstrate that astrocytes, but
not neurons, contain large deposits of Aβ42-555. Scale bars: 20 μm.
(TIF 2925 kb)
Additional file 2: Aβ inclusions co-localize with condensed nuclei of
dead cells. Aβ42-555 protofibril exposed cultures labelled with TUNEL
confirm that Aβ42-555 co-localizes with nuclei of dead cells. Scale bar:
20 μm. (TIF 716 kb)
Additional file 3: Intracellular localization of large Aβ42-555 inclusions
in astrocytes. Intersections from a 3D z-stack of an astrocyte exposed to
Aβ42-555 protofibrils demonstrate that Aβ42-555 deposits are located
intracellularly (arrow heads). DAPI (blue), GFAP (green) and Aβ42-555 (red).
Scale bars: 10 μm. (TIF 2239 kb)
Additional file 4: Immunostainings with Aβ42 specific antibodies
confirm Aβ42 protofibril inclusions in astrocytes. After 24 h Aβ protofibril
exposure, co-cultures were fixed and stained with GFAP and four different
Aβ antibodies; mAb1C3 (a), 6E10 (b), mAb158 (c) and polyclonal Aβ42
antibody (d). All antibodies detect extensive intracellular Aβ accumulation in
astrocytes. Scale bars: 20 μm. (TIF 3705 kb)
Additional file 5: Astrocytes differentiated in the presence of CNTF
contain Aβ deposits. Pure (CNTF-treated) astrocytic cultures exposed to
Aβ42-555 protofibrils demonstrate that astrocytes contain large
intracellular deposits of Aβ42-555. Scale bar: 20 μm. (TIF 1446 kb)
Additional file 6: Time-lapse movie from 30 min to 24 h following
Aβ42-555 protofibril administration shows that astrocytes, but not neurons
accumulate Aβ42-555 protofibrils over time. Images are captured in 10 min
intervals. (MP4 5271 kb)
Additional file 7: Aβ deposits in GFAP-positive astrocytes in the AD
mouse brain. Immunohistochemistry of tg-ArcSwe mouse brain sections
confirms that Aβ co-localizes with GFAP-positive astrocytes surrounding
the plaques. Aβ (red), GFAP (green). Scale bar: 20 μm. (TIF 1591 kb)
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Additional file 8: No accumulation of Aβ42 monomers in the co-cultures.
After 24 h Aβ40-555 monomer exposure of the cell cultures, no detectable
Aβ40-555 is present in astrocytes (GFAP). Scale bar: 20 μm. (TIF 1768 kb)
Additional file 9: Time-lapse movie starting 24 h after Aβ42-555
protofibril addition. Aβ42-555 accumulation induced formation of
enlarged, dynamic vacuoles in the astrocytes. The giant vacuoles
eventually shrink or collapse, concurrently as new vacuoles appear in the
same astrocyte. Images are captured in 10 min intervals. (MP4 3765 kb)
Additional file 10: Time-lapse movie captured at day 5 after Aβ42
protofibril addition. Enlarged vacuoles form and fuse in the astrocytes
resulting in giant vacuoles with a diameter of ~50 μm. Images are
captured in 5 min intervals. (MP4 2072 kb)
Additional file 11: Aβ co-localizes with endosomal markers. Double
stainings of Aβ42 protofibril exposed cell cultures with antibodies to Aβ/
Rab5 or Aβ/Rab7 demonstrate a clear co-localization of Aβ inclusions and
the early endosomal marker Rab5. Some co-localization is also noted for
Aβ and the late endosomal marker Rab7. Scale bars: 20 μm. (TIF 1930 kb)
Additional file 12: Aβ42 protofibrils do not directly induce neuronal cell
death. Cortical neurons were exposed to 0.1 μM Aβ42 protofibrils for 48 h
and TUNEL assay was performed to measure the number of apoptotic
neurons. No significant differences are seen in the number of TUNEL
positive cell nuclei or in the numbers of total cell nuclei compared to
untreated neurons. (TIF 140 kb)
Additional file 13: Aβ42 protofibril characterization. No considerable
difference is noticed comparing serially diluted Aβ42 protofibrils and
Aβ42-555 protofibrils with the Aβ protofibril selective mAb158 ELISA.
(TIF 149 kb)
Abbreviations
12 DIV: 12 days in vitro; AD: Alzheimer’s disease; Aβ: amyloid beta; BSA: bovine
serum albumin; CNPase: 2',3'-Cyclic-nucleotide 3'-phosphodiesterase;
CNTF: cilliary neurotrophic factor; CSF: cerebrospinal fluid; E14: embryonal day
14; ECL: enhanced chemiluminescence; GFAP: glial fibrillary acidic protein;
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protein-1; LAMP-2: lysosome-associated membrane protein-2; MSD: multiple
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